A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Ian McGowan,Sylvain Chawki,Craig W. Hendrix,Peter A. Anton,Mark A. Marzinke,Rhonda M. Brand,Jarret Engstrom,Lisa C. Rohan,Kaleab Z. Abebe,Nicola Richardson-Harman,Aaron Siegel,Alex Reinhart,John Steytler,Ron Stall,Hans M. L. Spiegel,Beatrice A. Chen,Sharon L. Achilles,Cindy Jacobson,Elena Khanukova,Ross D. Cranston

A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

2021

The Combination HIV Antiretroviral Rectal Microbicide-3 (CHARM-03) study was a randomized, open-label, crossover Phase 1 safety and pharmacokinetic (PK) study of oral maraviroc (MVC) and MVC 1% gel...

Keywords:

Pharmacology
charm
human immunodeficiency virus
Microbicide
Maraviroc
open label
Pharmacokinetics
Crossover
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations